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Abstract 
Biofilm microorganisms are known to have a much higher tolerance to antimicrobials 
compared to their planktonic equivalents. As a result, traditional antimicrobial susceptibility 
testing may not extrapolate to clinical treatment of infections of biofilm origin. As a result, 
there is a need to not only develop antimicrobials with antibiofilm activity, but also suitable 
in vitro testing methods for their evaluation. In this study, we report on a novel method of 
antibiofilm testing using a thermo-reversible matrix (Poloxamer 407), coupled with 
live/dead staining of bacteria cultured from the matrix.  Pseudomonas aeruginosa (NCIMB 
8626) was cultured in medium containing Poloxamer 407 at 37°C for 24 h to generate 
biofilms.  The preparation was cooled to liquefy the poloxamer and allow recovery of the 
biofilm cells, which were then stained with Syto9 to determine viability following exposure 
to four antimicrobials (polyhexanide, octenadine dihydrochloride, providone-iodine and 
silver carbonate).  Over an 8 min time period, fluorescence levels were 
spectrophotometrically measured and compared with bacterial controls, cultured in the 
absence of poloxamer and without antimicrobial.  Untreated cells showed no reduction in 
viability over this period.  Importantly, planktonic cells were more susceptible to test agents 
compared with those of a ‘biofilm’ phenotype cultured in Poloxamer.  Antibiofilm activity 
was evident for all of the test agents, with highest relative activity seen with octenadine 
dihydrochloride.  In summary, a novel and relatively rapid approach to screen compounds 
for antibiofilm activity has been described.  The method uses standard laboratory 






Biofilms are defined as microbial communities, often attached to a solid surface, where the 
microbial cells are embedded within a self-generated extracellular polymeric matrix.1  Such 
biofilm cells have properties that are distinct from their ‘free-living’ or planktonic 
counterparts that typically grow as individual organisms in a liquid environment.  A defining 
feature of biofilm cells is their increased tolerance to many antimicrobial agents2 and host 
defence molecules. 
In recent decades, it has become apparent that a significant number of human infections 
have a biofilm origin. Importantly, in the case of hospital-acquired infections, reports have 
indicated that over 65% of these are caused by biofilms.1  In addition, biofilms on medical 
devices frequently serve as a reservoir of infectious organisms, which are often protected 
from eradication by host defences or antimicrobials because of their location away from 
vascularised tissue.  
Biofilm cells are known to be more tolerant of antimicrobial agents compared with 
planktonic equivalents.  The reasons for this are complex, multifactorial and in part, relate 
to the surrounding EPS matrix, which may serve to sequester or neutralise antimicrobial 
agents, or promote the adaptation of cells to a phenotype that renders them more tolerant. 
Cells embedded in the biofilm also demonstrated variable growth rates and metabolic 
activity at different locations within the biofilm, or exhibit differential expression of 
resistance related genes when in a biofilm.23   
In recent years, there has been significant interest in the involvement of biofilms in 
impairing wound healing.3,4  Chronic wounds are defined as those that do not progress 
through an expected and orderly reparative process over a 3 month period.5  The presence 
of a recalcitrant biofilm could impede normal wound healing by actively producing 
hydrolytic enzymes that induce tissue damage, or promote a continuous state of 
inflammation leading to damage and a inappropriate healing responses.6,7 As a 
consequence, there is urgent need to develop novel antibiofilm compounds with the 
capacity to be incorporated into wound dressing technology to disrupt wound biofilms and 
reduce healing time for patients.8  With this focus, there is an associated need to produce 
simple and rapid methods, which can be used to assess the effectiveness of novel 
compounds against biofilms.9  
Currently there is a range of broad-spectrum antimicrobial agents which can be 
incorporated into wound dressings, the most common being various analogues of silver, 
such as nanocrystalline silver, silver sulfadiazine and ionic silver. Other broad-spectrum 
wound care antimicrobials include iodine, chlorhexidine, polyhexamethyl-biguanide 
(PHMB), honey, acetic acid and potassium permanganate, which can be impregnated into 
the wound dressing itself or in some cases, used as a solution for irrigation prior to dressing 
application.  
To date, increasing numbers of investigations have used different in vitro and in vivo models 
to examine the efficacy of common (and novel) wound antimicrobials to disrupt and kill 
wound biofilms.           
The ‘gold standard’ type of wound biofilm model could be seen as an animal model, or 
human patient with a chronic, non-healing wound.  These models would naturally replicate 
the exact environmental conditions and surface sub-strata that would promote biofilm 
development.  However, the use of in vivo modelling inherently contains uncontrollable 
elements of the host i.e., immune function, stress levels and mobility rates. In addition, 
supporting an in vivo model, such as a mouse, rat or pig can be very costly in terms of 
maintaining the minimum standards expected by animal welfare regulations; likewise, a 
human patient with a chronic wound will require regular visits and commitment from a 
wound health specialist for treatment and monitoring. In either case, in vivo modelling 
brings with it a range of added compilations, costs and time constrains associated with 
ethical research.       
There are a variety of in vitro models which have been employed to assess the efficacy of 
wound care technologies at disrupting infective biofilms. Thorn et al.,10 developed a model 
that utilised a flow-cell that allowed perfusion of simulated wound fluid through a porous 
matrix on which the biofilm cells had attached, thereby allowing the researcher to measure 
the antibiofilm effects of novel wound dressings. This type of system however, requires 
peristaltic pumps, bespoke containers and incubators for analysis, which significantly 
increase the initial setup costs.  
Other methods to assess the properties of antibiofilm compounds have used ‘off the shelf’ 
devices such as the Calgary Biofilm Device (CBD) or similar microtitre plate-based 
systems.11,12,13  With the CBD, biofilms of a particular microbial species are cultured on a 
range of pegs inserted into a microtitre plate with growth media and once developed, the 
pegs (and biofilm) can be removed and subjected to a range of antimicrobial susceptibility 
testing.  A key benefit of using this type of device is the number of simultaneous replicates 
that can be performed due to the device developed around a standard 96-well plate model.  
To date, there has been accumulating interesting in the use of poloxamer polymers for 
biofilm research. Poloxamers are inert, non-ionic, co-polymers, which can be dissolved in 
standard bacteriological culture media such as Muller-Hinton Broth or Tryptone Soya Broth. 
A key feature of poloxamers is their thermo-reversible properties. When dissolved in a 
medium at a temperature below 15oC (approximately), poloxamers are liquid; however, 
increasing the temperature above 15oC, causes the poloxamer to transform to a semi-solid 
gel, which can then be re-liquefied by lowering the temperature below 15oC. Importantly, it 
has already been reported that microorganisms cultured in a semi-solid poloxamer matrix 
form micro-colonies exhibiting a biofilm phenotype with increased tolerance to 
disinfectants, antimicrobials and silver containing wound dressings.14,15,16  The thermo-
reversible nature of poloxamers, coupled with their ability to induce a biofilm phenotype, 
makes it an attractive material to investigate the efficacy of antibiofilm compounds.  In this 
present investigation, we have evaluated the use of poloxamer within a 96-well plate model 
as a novel screening approach to assess antibiofilm activity of 4 different compounds 
previously used in the management of chronic wounds. 
 
Materials and methods 
All microbiological culture media and reagents were supplied by Oxoid Ltd (Basingstoke, 
Hampshire, UK) unless otherwise stated and were prepared as recommended by the 
manufacturer. Poloxamer 407 (Lutrol F127; Sigma, Poole, UK) for use in biofilm 
development was prepared at 30% (w/v) in Tryptic Soy Broth (TSB). The medium was 
sterilised in 250-ml volumes by autoclaving, and then liquefied at 5oC. Sodium Chloride 
Peptone Broth (SCPB) was also sterilised by autoclaving.       
Preparation of microbial biofilms in Poloxamer 407 
An overnight culture of Pseudomonas aeruginosa (NCIMB 8626) was prepared in TSB at 35oC 
in a humidity controlled incubator. Dilution of this culture in TSB was performed to give a 
standardised optical density (OD) of 0.8 at 620nm.  A 100-µl volume of the diluted culture 
was inoculated into 10 ml of liquefied (chilled) poloxamer-TSB medium and vortex mixed to 
ensure homogenous cell distribution. The viable cell count of P. aeruginosa in the 
poloxamer matrix was approximately 105 colony forming units (cfu)/ml, as determined by 
quantitative culture on solid agar media. Two hundred and fifty-µl volumes of inoculated 
poloxamer-TSB medium were added to 1.5 ml microcentrifuge tubes and these were 
incubated at 35oC in a humidity-controlled incubator for 24 h to generate biofilm 
phenotypes.  Planktonic control cultures of P. aeruginosa NCIMB 8626 were similarly 
prepared in TSB medium devoid of poloxamer. 
Recovery of biofilm cells 
After 24 h incubation, the microcentrifuge tubes were ‘flash cooled’ at -70oC for 2-3 min to 
liquefy the poloxamer. A 500-µl volume of chilled (5-6oC) SCPB was added to each 
poloxamer biofilm and mixed by repeated pipetting (this step prevented the poloxamer 
from re-solidifying when returned to room temperature).  Bacteria were then harvested by 
centrifugation (3000 g for 5 min). 
Susceptibility testing  
Test antibiofilm compounds were prepared in distilled water and were 0.1% (v/v) 
polyhexanide (Arch UK Biocides Ltd, Castleford, UK), 0.1% (v/v) octenadine dihydrochloride 
(Shulke, Sheffield, UK), 1% (w/v) providone-iodine (Vetasept, Animal Care Ltd, York, UK) and 
1% (w/v) silver carbonate (Fisher Scientific Ltd, Loughborough, UK).   
A 100-µl volume of test antibiofilm was added to the recovered bacterial cell pellets and 
incubated at 18°C for 1 min periods to a maximum of 8 min. Negative controls used 100 µl 
of sterile deionised water in place of the antibiofilm agent. After incubation, 1 ml of 
neutralising solution (lecithin NaCL buffered peptone; Heipha GmbH, Eppelheim, Germany) 
was added for polyhexanide and octenadine dihydrochloride treated samples, whilst sodium 
thioglycolate was used as a neutraliser for both silver carbonate and iodine. 
The treated cells were centrifuged and washed with SCPB to remove any remaining 
neutraliser and re-suspended in 100 µl of SCPB together with 100 µl of Syto9 live stain 
(Baclight, Life Technologies, Paisley, UK) prepared according to manufacturer’s instructions. 
Incubation with Syto9 was for 15 min in the dark and at room temperature. Two 100-µl 
volumes were then transferred to separate wells of a black-clear bottom 96 well plate. The 
plate was scanned using an optical plate reader (Varioskan; Thermo-scientific, 
Loughborough, UK) measuring excitation/emission at 480/500 nm at 7 separate points in 
each well and the data captured using dedicated software. 
Statistical analysis 
The raw data from the Syto9 florescence emission (at 500 nm) was exported to excel 
(Microsoft). The data was normalised against the mean time zero readings for the negative 
controls and the percentage reduction in fluorescence over the 8 min period of analysis 
calculated. Statistical analysis performed using GraphPad Prism (GraphPad Prism 5.01, 
California, USA). 
Results 
Figure 1 illustrates the results of reduction in fluorescence (reduced viability) of P. 
aeruginosa following exposure to 0.1 % polyhexanide.  It was evident that there was no 
reduction in viability of P. aeruginosa for either planktonic or biofilm control preparations in 
the absence of the antimicrobial.  Both planktonic and biofilm preparations treated with 
0.1% polyhexanide showed increasing reduction in viability over the 8 min exposure period 





 Figure 1. Reduction in fluorescence caused by 0.1% polyhexanide from viable P. aeruginosa 
cells stained with Syto9.  Solid black line (▪) = biofilm control (TSB + 30% poloxamer + Sterile 
H2O). Blue line (○) = bioﬁlm test (TSB + 30% poloxamer + polyhexanide). Green line (●) = 
planktonic control (TSB + Sterile H2O). Red line (□) = planktonic test (TSB + polyhexanide). 
Error bars show ± SEM (n=14; 2 biofilm/planktonic samples read at 7 different spatial 
points). *Relative Fluorescence Units. 
 
Interestingly, in the case of treatment with both 0.1% octenadine dihydrochloride (figure 2) 
and 1% silver carbonate (figure 3), whilst both biofilms and planktonic preparations were 
killed by the antimicrobials, there was a notable delay in antimicrobial effect against the 
biofilms preparations.  Treatment using 1% providone-iodine (Figure 4) again showed 
reduced antimicrobial activity against biofilm derived cells, however this was not seen as a 
delayed effect, but was evident by a greater reduction in planktonic cell viability at all time 
points.  
 Figure 2. Reduction in fluorescence by 0.1% octenadine dihydrochloride from viable P. 
aeruginosa cells stained with SYTO9. Solid black line (▪) = biofilm control (TSB + 30% 
poloxamer + Sterile H2O). Blue line (○) = bioﬁlm test (TSB + 30% poloxamer + octenadine 
dihydrochloride). Green line (●) = planktonic control (TSB + Sterile H2O). Red line (□) = 
planktonic test (TSB + octenadine dihydrochloride). Error bars show ± SEM (n=14; 2 





 Figure 3. Reduction in fluorescence by 1% silver carbonate from viable P. aeruginosa cells 
stained with SYTO9. Solid black line (▪) = biofilm control (TSB + 30% poloxamer + Sterile 
H2O). Blue line (○) = bioﬁlm test (TSB + 30% poloxamer + silver carbonate). Green line (●) = 
planktonic control (TSB + Sterile H2O). Red line (□) = planktonic test (TSB + silver carbonate). 
Error bars show ± SEM (n=14; 2 biofilm/planktonic samples read at 7 different spatial 




 Figure 4. Reduction in fluorescence by 1% providone-iodine from viable P. aeruginosa cells 
stained with SYTO9. Solid black line (▪) = biofilm control (TSB + 30% poloxamer + Sterile 
H2O). Blue line (○) = bioﬁlm test (TSB + 30% poloxamer + Providone-iodine). Green line (●) = 
planktonic control (TSB + Sterile H2O). Red line (□) = planktonic test (TSB + providone-
iodine). Error bars show ± SEM (n=14; 2 biofilm/planktonic samples read at 7 different 














In recent years, the treatment of microbial infections has become increasingly problematic 
due to the emergence of microbial species with an acquired resistance to over-prescribed 
antibiotics. This antimicrobial resistance has primarily arisen due to selective pressures of 
excessive and non-targeted use of antibiotics as part of clinical therapy.17  In addition, with 
increasing use of implanted medical devices in modern medicine, such as prosthetics, 
intravenous and urinary catheters, the prevalence of biofilm-originating infections has also 
increased.  
The reason why biofilms are more tolerant to antimicrobials is multifactorial and most likely 
relates to the poor penetration of the agent through the biofilm matrix (due to diffusion 
limitation and sequestration) or inactivation of the agent by the EPS of the biofilm.  Even if 
the agent can access the biofilm cells, it is thought that low metabolic activity of members 
of the biofilm population or those actually expressing an altered and more resistant 
phenotype (i.e. persister cells) are able to survive. To counter these problems, there is 
clearly an urgent need to develop novel antimicrobial therapies that also exhibit activity 
against biofilms.  Of course, methodology that allows the efficacy of antimicrobial function 
to be assessed against biofilms is a necessary component of this antimicrobial development.  
Chronic wounds are defined as those that do not heal in an orderly fashion and typically 
beyond a 3-month time frame.5  The impact of chronic wounds is not limited to patient 
morbidity, but also increases healthcare costs. It was reported that in 1999, annual costs 
associated with chronic wounds in the USA alone, exceeded $1 billion.18 This cost is 
continually increasing given the changing demographics of societies, where the over 80 year 
olds represent is the most rapidly expanding age group.  
In recent years, the occurrence of biofilms within wounds has been implicated with 
impaired wound healing.19,20  The exact reasons why biofilms delay wound healing remain to 
be established. It has, however, been proposed that production of microbial virulence 
factors in the wound environment, such as hydrolytic enzymes and toxins, directly promote 
tissue damage.21  In addition, a continual stimulation of the host’s immune response 
through wound colonisation by a recalcitrant biofilm may also lead to indirect tissue damage 
from the immune factors and cells.   
Pseudomonas aeruginosa is an opportunistic bacterial pathogen and one that is adept at 
biofilm formation.22 This bacterial species is also renowned for its high resistance to many 
antimicrobials and the fact that it can also produce biofilms exacerbates this problem.  
Pseudomonas aeruginosa is a frequent coloniser of wounds and also has been implicated 
with chronic wounds and as such, this species was seemed to be an appropriate model 
organism to use in the present investigation.    
 
Given the problems outlined above, this present study investigated a novel approach for the 
screening of antimicrobials that might exhibit activity against P. aeruginosa biofilm cells. 
These ‘biofilm’ cells were cultured within a thermo-reversible gel matrix using Poloxamer 
407, which has been previously proven to induce a biofilm phenotype.  Test antimicrobials 
were those that have previously been used to treat wound infections.  The observation that 
3 of the 4 test agents (i.e. 0.1% octenadine dihydrochloride, 1% silver carbonate and 1% 
povidone iodine) exhibited reduced activity for P. aeruginosa cultured in the Poloxamer 
matrix compared to planktonic culture would indeed indicate successful generation of 
bacteria with a biofilm phenotype. 
In the case of both octenadine dihydrochloride and silver carbonate, increased periods of 
antimicrobial exposure were required to generate equivalent antimicrobial effects as those 
evident with planktonic cultures. The reason for this is unclear, but could relate to factors 
such as alterations in cell wall structures; or the presence of EPS surrounding the cell which 
can either prevent antimicrobial contact with the cell membrane or limit penetration itself 
into the cell. 
A different profile of tolerance was seen for biofilm cells exposed to povidone iodine (figure 
4). In these cases, at any given time point a higher proportion of viable cells was evident for 
the biofilm cells compared with the planktonic cells.  It is tempting to speculate here that a 
subpopulation of cells (i.e. persister cells) is present in the biofilm that were able to resist 
the effects of 1 % povidone iodine.  Further investigation, with longer exposure periods 
would be needed to test this hypothesis.  Interestingly, comparable antimicrobial activity for 
both biofilm and planktonic cells was evident with 0.1 % polyhexanide (figure 1), suggesting 
that an antimicrobial mechanism could be present that was unaffected by the biofilm 
phenotype generated by the poloxamer.   
There are clear benefits to this novel antimicrobial screening method.  Key amongst these 
are that cells of a biofilm phenotype can be tested and a more relevant antimicrobial 
efficacy determined against likely wound colonisers.  However, during these experiments 
some potential limitations were noted, such as unknown interactions between the 
antimicrobial and the Syto9 stain. It is quite possible that certain antimicrobials i.e. bleach 
based disinfectants or surfactants, may have unwanted reactions with fluorescent stains, 
potentially reducing the data accuracy.  Overall, this method was able to screen multiple 
antimicrobials and can readily be expanded to culture other microbial species. 
Standard laboratory materials were used in this research, although there is the need for a 
spectrophotometer that can detect Syto9 fluorescence.  It is envisaged that with the 
anticipated advent of newer antimicrobial agents for use in wound care, the described 
methodology will aid manufacturers in identifying agents with antibiofilm properties. 
Overall this will ultimately benefit the patient and clinicians through a better understanding 
of the biofilm/antimicrobial interaction, thus reducing the healing time and costs to the 
health service.      
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